Major market opportunity with limited current treatment options...

Major market opportunity with limited current treatment options

Click here to view the reference

OSA is a major public health problem and represents a significant market opportunity for Incannex.

It is a lethal disease that increases the risk of numerous health complications, not least an increased risk of
cardiovascular morbidity. Many people with OSA develop high blood pressure (hypertension), which can
increase the risk of heart disease. The more severe the OSA, the greater the risk of coronary artery disease,
heart attack, heart failure and stroke.

The main current treatment option is the mechanical CPAP device, however, patient compliance to CPAP
devices is low due to discomfort and claustrophobia resulting from pressurised air being pumped into the
patient’s nose and/or mouth during sleep. Regardless of this intrusive and uncomfortable mechanical
treatment option, the global annual market for OSA detection and treatment using CPAP devices is over
US$10B per annum and growing.

OSA is a highly prevalent condition affecting approximately 30M adults in the USA. It is calculated that the
annual economic burden of undiagnosed sleep apnoea among U.S. adults is approximately $149.6 billion per
annum. The estimated costs include $86.9 billion in lost productivity, $26.2 billion in motor vehicle accidents
and $6.5 billion in workplace accidents

Even in Australia, Deloitte Access Economics has estimated that the direct economic costs due to OSA were
more than $21B per annum. This estimation was made by assessing loss of workdays and morbidity caused
by OSA through cardiovascular problems, depression, motor vehicle accidents, workplace accidents and type
2 diabetes.
There is no existing registered pharmacotherapy (drug) treatment option for people with OSA. Incannex
anticipates greatly improved patient treatment compliance and outcomes from a pharmaceutical product,
which could be IHL-42X should it prove successful under clinical assessment.

-------------------------------------------------------------------------------------------------
Resmed Website

Quotes

Sleep apnea is more than 936 million people worldwide

Sleep apnea impacts more than 936 million people worldwide

Source: Benjafield AV et al, “Estimation of the global prevalence and burden of obstructive sleep apnoea: A literature-based analysis”. Vol 7:8; 687-98. Lancet Respir Med 2019. Statistic based on US findings for adults aged 30-69.

These numbers are huge !!